Wilburn Bolton, MD
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1225267289
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Abbott at 36.9% of the total. 2025 is the largest year on record at $17,127, more than ten times the $931 reported in 2019.
Across 706 payments — averaging $74.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$19K
- Lilly USA, LLC$16K
- Amgen$6K
- Xeris Pharmaceuticals, Inc.$3K
- Novo Nordisk$2K
- Bayer$736
- plus $5K from 41 others
What the payments were for
- Consulting fees$8,45916%
- Speaking & faculty fees$29,04456%
- Travel & lodging$2,4785%
- Food & beverage$12,24423%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$14,472
- FREESTYLE LIBRE 3$8,845
- FreeStyle Libre Pro$6,863
- TEPEZZA$5,254
- GVOKE HYPOPEN$2,550
- FreeStyle Libre$2,347
- MINIMED 780G$270
- Ozempic$125
- LOKELMA$122
- Korlym$115
- FARXIGA$105
- RETEVMO$100
How this compares
$52,293 in reported general payments places this provider in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $274,722 |
| MounjaroTirzepatide | 178 | $271,379 |
| JardianceEmpagliflozin | 108 | $124,040 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $78,659 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $68,984 |
| JanuviaSitagliptin Phosphate | 67 | $56,099 |
| FarxigaDapagliflozin Propanediol | 43 | $54,771 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $45,813 |
| TrulicityDulaglutide | 28 | $34,038 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $32,556 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $27,404 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $23,434 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 78 | $13,178 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $12,638 |
| NovologInsulin Aspart | 33 | $11,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $1,862 | $332,402226 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $16,419 | $308,190225 claims |
| Boehringer IngelheimJardiance | $222 | $124,040108 claims |
| MerckJanuvia | $13 | $56,09967 claims |
| AstraZenecaFarxiga | $527 | $54,77143 claims |
| AbbVieSynthroid | $84 | $6,40672 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $2,941310 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Mobile
- Anita KemmerlyMobile$13K
- Michael DavisMobile$12K
- Heather FishelMobile$11K
- Michael GalitzMobile$10K
- Jocelyn HewittMobile$9K
- Huey McDanielMobile$8K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
- Neil SchaffnerOpelika$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.